Travere says no FDA AdCom for Filspari review (TVTX:NASDAQ)

Group 1 - Travere Therapeutics (NASDAQ:TVTX) experienced a ~27% increase in premarket trading on Wednesday [4] - The company received notification from the FDA that an advisory committee meeting will not be required for the review of a potential label expansion for its kidney treatment [4]